10-KPeriod: FY2013

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2013

Filed February 18, 2014For Securities:DGX

Summary

Quest Diagnostics, a leader in diagnostic testing information services, generated $7.1 billion in net revenues in 2013, processing approximately 147 million test requisitions. The company is executing a five-point strategy focused on restoring growth, driving operational excellence, simplifying the organization, refocusing on core diagnostic information services, and disciplined capital deployment. Key initiatives include Project Restore to drive profitable growth through sales and marketing enhancements and expanding esoteric testing, and Project Invigorate to achieve significant cost savings, with over $250 million realized in 2013 and a run-rate savings target of $700 million by the end of 2014. Quest Diagnostics leverages its extensive national network, broad test menu, and strong medical and scientific expertise to serve a diverse customer base including physicians, hospitals, health plans, and employers. The company is also investing in innovation, particularly in areas like companion diagnostics and personalized medicine, and enhancing its healthcare IT solutions like Care360. Despite a competitive landscape and reimbursement pressures, Quest Diagnostics aims to drive long-term growth by focusing on its core strengths and strategic initiatives.

Financial Highlights

56 data points
Beta

Revenue

$7.15B

39.5% Gross Margin

Net Income

$849.00M

11.9% Net Margin

EPS (Diluted)

$5.54

Total Assets

$8.95B

Cash & Equivalents

$187.00M

Free Cash Flow

$421.00M

Financial Statements
Beta
Revenue$7.15B
Cost of Revenue$4.33B
Gross Profit$2.82B
SG&A Expenses$1.70B
Operating Expenses$5.67B
Operating Income$1.48B
Net Income$849.00M
EPS (Basic)$5.58
EPS (Diluted)$5.54
Shares Outstanding (Basic)152.00M
Shares Outstanding (Diluted)153.00M

Key Highlights

  • 1In 2013, Quest Diagnostics generated $7.1 billion in net revenues, processing approximately 147 million test requisitions, demonstrating its significant scale in the diagnostic information services market.
  • 2The company is executing a five-point business strategy initiated in 2012, with a strong focus in 2013 on 'Restore Growth' through initiatives like Project Restore, aiming to exceed market growth rates.
  • 3Operational excellence is a key priority, driven by Project Invigorate, which achieved over $250 million in realized savings in 2013 and is targeting $700 million in run-rate savings by the end of 2014.
  • 4Quest Diagnostics is strategically refocusing on its core 'Diagnostic Information Services' business, divesting non-core assets like the HemoCue and Enterix businesses in 2013.
  • 5The company is committed to disciplined capital deployment, including a 10% increase in its quarterly dividend in January 2014 and returning over $1 billion to stockholders through share repurchases in 2013.
  • 6Quest Diagnostics maintains a leading market position due to its extensive national network, broad test menu, robust logistics, and a large scientific staff of over 725 MDs and PhDs.
  • 7The company is actively investing in innovation, particularly in gene-based and esoteric testing, companion diagnostics, and healthcare IT solutions like the Care360 suite to enhance customer value and loyalty.

Frequently Asked Questions

Quest Diagnostics is the world's leading provider of diagnostic testing information services. They offer a wide range of clinical laboratory and anatomic pathology testing, information, and insights to empower healthcare decisions for patients, physicians, hospitals, health plans, employers, and others. They hold a leading position in routine, gene-based, and esoteric testing in the United States.

Quest Diagnostics is focused on a five-point strategy: 1) Restore growth through initiatives like Project Restore and a focus on sales, marketing, and esoteric testing; 2) Drive operational excellence via Project Invigorate for cost savings and efficiency; 3) Simplify the organization; 4) Refocus on diagnostic information services by divesting non-core assets; and 5) Deliver disciplined capital deployment, including dividends and share repurchases. Project Invigorate has already yielded significant savings, and the company aims to continue this trend.

Quest Diagnostics' competitive advantages include its extensive nationwide network of laboratories and patient service centers, the broadest test menu in the industry, strong logistics capabilities, and a large, highly qualified medical and scientific staff. They are also a leading innovator, focusing on developing new tests and services, particularly in gene-based and esoteric testing, companion diagnostics for personalized medicine, and advanced healthcare information technology solutions like their Care360 suite.

Key risks include the highly competitive nature of the clinical testing industry, pressure on reimbursement rates from government payers (like Medicare and Medicaid) and third-party health plans, regulatory changes (particularly concerning healthcare reform and FDA oversight of lab-developed tests), potential IT system failures, and the inherent risks associated with business development activities and integrating acquisitions. Reimbursement pressure and regulatory changes are significant ongoing concerns.